TrialDiabetes, obesity & metabolism2020

Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers.

Marjolein Y A M Kroonen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.